Reviews on Long COVID: A scope of the literature.:Update April 2024

• For this update, we identified 36 published reviews and 63 review protocols for Long COVID. • The number of reviews (n=36) is fewer than in January 2024 (n=42), and October 2023 (n=46) but more than in July 2023 (n=31), and similar to April 2023 (n=37). • Most reviews were focused on the prevalence of symptoms or effects (21/36), which remains consistent with earlier reports. • We identified five reviews on treatment or rehabilitation, and five on risk factors with or without prevalence; both numbers are lower than last quarter (treatment n=7 and risk n=9). • We identified two reviews on pathobiology or mechanisms; the same number as in the January 2024 report. • The number of protocols (n=63) was greater than in January 2024 (n=42), October (n=44) and July (n=53), but less than in April 2023 (n=73). • As in previous reports, the largest two categories of protocols focused on the prevalence of symptoms or effects (24/63), and treatment or rehabilitation (21/63). • Eight protocols were focused on risk factors with or without prevalence, and four were on pathobiology or mechanisms; these numbers are similar to those in previous reports.